Your browser doesn't support javascript.
loading
[Influence of doxorubicin inclusion into phospholipid nanoparticles on tumor accumulation and specific activity]. / Vliianie vkliucheniia doksorubitsina v fosfolipidnye nanochastitsy na nakoplenie v opukholi i spetsificheskuiu aktivnost'.
Medvedeva, N V; Torkhovskaya, T I; Kostryukova, L V; Zakharova, T S; Kudinov, V A; Kasatkina, E O; Prozorovskiy, V N; Ipatova, O M.
Afiliação
  • Medvedeva NV; Institute of Biomedical Chemistry, Moscow, Russia.
  • Torkhovskaya TI; Institute of Biomedical Chemistry, Moscow, Russia.
  • Kostryukova LV; Institute of Biomedical Chemistry, Moscow, Russia.
  • Zakharova TS; Institute of Biomedical Chemistry, Moscow, Russia.
  • Kudinov VA; Institute of Biomedical Chemistry, Moscow, Russia.
  • Kasatkina EO; Institute of Biomedical Chemistry, Moscow, Russia.
  • Prozorovskiy VN; Institute of Biomedical Chemistry, Moscow, Russia.
  • Ipatova OM; Institute of Biomedical Chemistry, Moscow, Russia.
Biomed Khim ; 63(1): 56-61, 2017 Jan.
Article em Ru | MEDLINE | ID: mdl-28251952
The specific activity of drug formulation of doxorubicin embedded into phospholipid nanoparticles with diameter less than 30 nm ("Doxolip") was studied in mice LLC carcinoma. Doxolip was prepared according to technology that was elaborated in Institute earlier. Doxorubicin tumor accumulation after intraperitoneal administration (at 4 h) was 4.5 times higher for Doxolip, than for free doxorubicin. The study of doxorubicin antitumor activity in developing tumor after single intravenous administration, 48 h after inoculation, showed, that: 1) tumor growth inhibition of Doxolip was observed at 6th day, while it was only at 11th day for free doxorubicin and revealed in less extent; 2) there was no antitumor effect of free doxorubicin at 8 days after administration of doses 2 and 4 mg/kg, but it was observed for Doxolip in dose-dependent manner, 10% and 30% correspondently. In experiment with developed tumor weekly Doxolip intraperitoneal administration (5 mg/kg, 3 weeks beginning from 7 days after inoculation) resulted in 56% decrease of tumor volume as compared with control. This parameter for free doxorubicin was 2.8 times lower. The obtained data indicate, that incorporation of doxorubicin into phospholipid nanoparticles with size up to 30 nm as delivery system increases its tumor accumulation and results to increase of specific activity both in intraperitoneal and in intravenous administration.
Assuntos
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Fosfolipídeos / Portadores de Fármacos / Carcinoma Pulmonar de Lewis / Nanopartículas / Antibióticos Antineoplásicos Limite: Animals Idioma: Ru Revista: Biomed Khim Ano de publicação: 2017 Tipo de documento: Article País de afiliação: Federação Russa País de publicação: Federação Russa

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Fosfolipídeos / Portadores de Fármacos / Carcinoma Pulmonar de Lewis / Nanopartículas / Antibióticos Antineoplásicos Limite: Animals Idioma: Ru Revista: Biomed Khim Ano de publicação: 2017 Tipo de documento: Article País de afiliação: Federação Russa País de publicação: Federação Russa